The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia

NCT07735104 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Cachexia
Cancer Cachexia Syndrome

Interventions

DRUG: QLS2319
DRUG: Placebo

Sponsor

Qilu Pharmaceutical Co., Ltd.